Phase III randomised trials comparing EGFR TKIs with chemotherapy in first-line therapy in EGFR-mutant nonsmall cell lung cancer
| First author [ref.] | Study name | Ethnicity | Patients with EGFR mutation n | EGFR TKI | Chemotherapy | ORR# % | PFS# months |
| Mok [28] | IPASS | Asians | 261 | Gefitinib (n=132) | Carboplatin/paclitaxel (n=129) | 71/47 | 9.5/6.3 (HR 0.48) |
| Mitsudomi [29] | WJTOG3405 | Asians | 117 | Gefitinib (n=58) | Cisplatin/docetaxel (n=59) | 62/32 | 98.2/6.3 (HR 0.49) |
| Maemondo [30] | NEJ002 | Asians | 228 | Gefitinib (n=114) | Carboplatin/paclitaxel (n=114) | 74/31 | 10.8/5.4 (HR 0.30) |
| Zhou [31] | OPTIMAL | Asians | 154 | Erlotinib (n=82) | Carboplatin/gemcitabine (n=72) | 83/36 | 13.1/4.6 (HR 0.37) |
| Rosell [32] | EURTAC | Caucasians | 173 | Erlotinib (n=86) | Doublets with platinum (n=87) | 71/47 | 9.58/5.5 (HR 0.37) |
| Wu [33] | ENSURE | Asians | 217 | Erlotinib (n=110) | Cisplatin/gemcitabine (n=107) | 63/34 | 11.0/5.5 (HR 0.34) |
| Sequist [34] | LUX-Lung 3 | Caucasians | 345 | Afatinib (n=230) | Cisplatin/pemetrexed (n=115) | 56/23 | 11.1/6.9 (HR 0.58) |
| Wu [35] | LUX-Lung 6 | Asians | 364 | Afatinib (n=242) | Cisplatin/gemcitabine (n=122) | 67/23 | 11.0/5.6 (HR 0.28) |
EGFR: epidermal growth factor receptor; TKI: tyrosine kinase inhibitor; ORR: objective response rate; PFS: progression-free survival; HR: hazard ratio. #: comparisons presented as EGFR TKI/chemotherapy.